Advertisement
Screener

Moleculin Biotech, Inc. (MBRX) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Moleculin Biotech, Inc. Operating Cash Flow

Moleculin Biotech, Inc. (MBRX) reported Operating Cash Flow of -$12.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13

  • Moleculin Biotech, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.66M.
  • Moleculin Biotech, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$6.11M.
  • Moleculin Biotech, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.37M.
  • Moleculin Biotech, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$7.22M.
  • Moleculin Biotech, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$22.73M.
  • Moleculin Biotech, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$23.86M.
  • Moleculin Biotech, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$23.59M.
  • Moleculin Biotech, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$27.64M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$6.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$12.77M
10-Q · filed 2026-08-13
-$18.13M
derived: sum of 3 quarters · filed 2026-08-13
-$25.36M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$6.11M
10-Q · filed 2026-05-14
-$11.48M
derived: sum of 2 quarters · filed 2026-05-14
-$18.70M
derived: sum of 3 quarters · filed 2026-05-14
-$24.28M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$5.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
-$12.59M
derived: sum of 2 quarters · filed 2026-03-18
-$18.17M
derived: sum of 3 quarters · filed 2026-08-13
-$22.73M
10-K · filed 2026-03-18
2025-09-30-$7.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$12.80M
derived: sum of 2 quarters · filed 2026-08-13
-$17.37M
10-Q · filed 2025-11-13
-$22.45M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$5.58M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$10.15M
10-Q · filed 2026-08-13
-$15.23M
derived: sum of 3 quarters · filed 2026-08-13
-$21.34M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$4.56M
10-Q · filed 2026-05-14
-$9.65M
derived: sum of 2 quarters · filed 2026-05-14
-$15.76M
derived: sum of 3 quarters · filed 2026-05-14
-$21.71M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$5.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18
-$11.20M
derived: sum of 2 quarters · filed 2026-03-18
-$17.14M
derived: sum of 3 quarters · filed 2026-03-18
-$23.86M
10-K · filed 2026-03-18
2024-09-30-$6.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$12.06M
derived: sum of 2 quarters · filed 2025-11-13
-$18.78M
10-Q · filed 2025-11-13
-$23.68M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$5.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$12.67M
10-Q · filed 2025-08-12
-$17.56M
derived: sum of 3 quarters · filed 2025-08-12
-$25.11M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$6.72M
10-Q · filed 2025-05-13
-$11.61M
derived: sum of 2 quarters · filed 2025-05-13
-$19.16M
derived: sum of 3 quarters · filed 2025-05-13
-$24.29M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$4.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21
-$12.45M
derived: sum of 2 quarters · filed 2025-03-21
-$17.57M
derived: sum of 3 quarters · filed 2025-03-21
-$23.59M
10-K · filed 2025-03-21
-$24.10M
10-K · filed 2024-03-22
2023-09-30-$7.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
-$12.68M
derived: sum of 2 quarters · filed 2024-11-08
-$18.69M
10-Q · filed 2024-11-08
-$25.95M
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30-$5.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$11.14M
10-Q · filed 2024-08-13
-$18.40M
derived: sum of 3 quarters · filed 2024-08-13
-$25.98M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$6.02M
10-Q · filed 2024-05-10
-$13.27M
derived: sum of 2 quarters · filed 2024-05-10
-$20.85M
derived: sum of 3 quarters · filed 2024-05-10
-$28.85M
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31-$7.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22
-$14.83M
derived: sum of 2 quarters · filed 2024-03-22
-$22.83M
derived: sum of 3 quarters · filed 2024-03-22
-$27.64M
10-K · filed 2024-03-22
2022-09-30-$7.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$15.58M
derived: sum of 2 quarters · filed 2023-11-13
-$20.38M
10-Q · filed 2023-11-13
-$24.64M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$8.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$12.81M
10-Q · filed 2023-08-10
-$17.06M
derived: sum of 3 quarters · filed 2023-08-10
-$21.35M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$4.80M
10-Q · filed 2023-05-10
-$9.06M
derived: sum of 2 quarters · filed 2023-05-10
-$13.35M
derived: sum of 3 quarters · filed 2023-05-10
-$20.13M
derived: sum of 4 quarters · filed 2023-05-10
2021-12-31-$4.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22
-$8.55M
derived: sum of 2 quarters · filed 2023-03-22
-$15.33M
derived: sum of 3 quarters · filed 2023-03-22
-$18.95M
10-K · filed 2023-03-22
2021-09-30-$4.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$11.07M
derived: sum of 2 quarters · filed 2022-11-10
-$14.69M
10-Q · filed 2022-11-10
-$17.82M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$6.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
-$10.40M
10-Q · filed 2022-08-12
-$13.53M
derived: sum of 3 quarters · filed 2022-08-12
-$18.90M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$3.62M
10-Q · filed 2022-05-11
-$6.75M
derived: sum of 2 quarters · filed 2022-05-11
-$12.12M
derived: sum of 3 quarters · filed 2022-05-11
-$17.05M
derived: sum of 4 quarters · filed 2022-05-11
2020-12-31-$3.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24
-$8.50M
derived: sum of 2 quarters · filed 2022-03-24
-$13.43M
derived: sum of 3 quarters · filed 2022-03-24
-$17.77M
10-K · filed 2022-03-24
2020-09-30-$5.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$10.30M
derived: sum of 2 quarters · filed 2021-11-10
-$14.65M
10-Q · filed 2021-11-10
-$19.32M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$4.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
-$9.28M
10-Q · filed 2021-08-11
-$13.95M
derived: sum of 3 quarters · filed 2021-08-11
-$17.28M
derived: sum of 4 quarters · filed 2021-08-11
2020-03-31-$4.34M
10-Q · filed 2021-05-12
-$9.02M
derived: sum of 2 quarters · filed 2021-05-12
-$12.35M
derived: sum of 3 quarters · filed 2021-05-12
-$17.69M
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31-$4.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24
-$8.00M
derived: sum of 2 quarters · filed 2021-03-24
-$13.35M
derived: sum of 3 quarters · filed 2021-03-24
-$17.20M
10-K · filed 2021-03-24
2019-09-30-$3.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
-$8.67M
derived: sum of 2 quarters · filed 2020-11-12
-$12.52M
10-Q · filed 2020-11-12
-$15.63M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30-$5.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12
-$9.19M
10-Q · filed 2020-08-12
-$12.30M
derived: sum of 3 quarters · filed 2020-08-12
-$15.12M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31-$3.85M
10-Q · filed 2020-05-11
-$6.96M
derived: sum of 2 quarters · filed 2020-05-11
-$9.78M
derived: sum of 3 quarters · filed 2020-05-11
-$13.24M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31-$3.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19
-$5.93M
derived: sum of 2 quarters · filed 2020-03-19
-$9.40M
derived: sum of 3 quarters · filed 2020-03-19
-$12.20M
10-K · filed 2020-03-19
2018-09-30-$2.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$6.29M
derived: sum of 2 quarters · filed 2019-11-12
-$9.09M
10-Q · filed 2019-11-12
-$11.48M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30-$3.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-16
-$6.27M
10-Q · filed 2019-08-16
-$8.66M
derived: sum of 3 quarters · filed 2019-08-16
-$10.28M
derived: sum of 4 quarters · filed 2019-08-16
2018-03-31-$2.81M
10-Q · filed 2019-05-13
-$5.20M
derived: sum of 2 quarters · filed 2019-05-13
-$6.81M
derived: sum of 3 quarters · filed 2019-05-13
-$8.74M
derived: sum of 4 quarters · filed 2019-05-13
2017-12-31-$2.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21
-$4.00M
derived: sum of 2 quarters · filed 2019-02-21
-$5.93M
derived: sum of 3 quarters · filed 2019-02-21
-$7.32M
10-K · filed 2019-02-21
2017-09-30-$1.61M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
-$3.54M
derived: sum of 2 quarters · filed 2018-11-13
-$4.93M
10-Q · filed 2018-11-13
-$6.10M
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30-$1.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10
-$3.32M
10-Q · filed 2018-08-10
-$4.49M
derived: sum of 3 quarters · filed 2018-08-10
2017-03-31-$1.39M
10-Q · filed 2018-05-14
-$2.56M
derived: sum of 2 quarters · filed 2018-05-14
2016-12-31-$1.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28
-$3.77M
10-K · filed 2018-03-28
2016-09-30-$2.60M
10-Q · filed 2017-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33
Theriva Biologics, Inc. (TOVX)United States$0.011B
Dare Bioscience, Inc. (DARE)United States$0.011B
Azitra, Inc. (AZTR)United States$0.010B-0.81
Medicus Pharma Ltd. (MDCX)$0.010B
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92